Maze Therapeutics (NASDAQ: MAZE) shifts principal accounting role to CFO

Did Maze Therapeutics report any disagreements related to Amy Bachrodt’s resignation?

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Terms

What leadership change did Maze Therapeutics (MAZE) disclose in this 8-K?

When will Maze Therapeutics’ Senior Vice President of Finance resign?

Who will serve as principal accounting officer at Maze Therapeutics after June 1, 2026?

What SEC item does this Maze Therapeutics (MAZE) 8-K relate to?

Maze Therapeutics stated that Amy Bachrodt’s resignation was not due to any disagreement with the company. This includes no issues relating to operations, policies, practices, or the company’s financial reporting, suggesting a routine leadership transition rather than a conflict-driven departure.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Maze Therapeutics, Inc. reported that Amy Bachrodt, its Senior Vice President of Finance, has given notice that she will resign effective June 1, 2026. The company states her resignation is not due to any disagreement regarding operations, policies, practices, or financial reporting. Following her departure, Chief Financial Officer Misbah Tahir will also serve as the company’s principal accounting officer, consolidating financial leadership under the CFO role.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Emerging growth company, principal accounting officer, Item 5.02, Nasdaq Stock Market LLC

4 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

principal accounting officer financial

"Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

Item 5.02 regulatory

"Item 5.02 Departure of Directors or Certain Officers; Election of Directors"

Nasdaq Stock Market LLC market

"MAZE | | The Nasdaq Stock Market LLC"

Nasdaq Stock Market LLC is the company that operates the Nasdaq electronic stock exchange, a large centralized marketplace where shares of publicly traded companies are listed and bought and sold. Think of it as a high-speed digital auction house and storefront combined: being listed there gives a company visibility and easier access to many buyers, while investors benefit from transparent prices, fast trades and regulated rules that help protect fair trading.

Understanding 8-K Material Events →

05/22/2026 - 05:24 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 18, 2026

Maze Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-42490	82-2635018
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)


171 Oyster Point Blvd., Suite 300
South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 850-5070

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock - par value $0.001 per share	MAZE	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026. Ms. Bachrodt’s resignation was not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices or on any matter relating to the Company’s financial reporting.

Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt’s departure.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Maze Therapeutics disclosed that Senior Vice President of Finance, Amy Bachrodt, will resign effective June 1, 2026. The company also stated that its Chief Financial Officer, Misbah Tahir, will assume the role of principal accounting officer after her departure.

Amy Bachrodt’s resignation as Senior Vice President of Finance will be effective June 1, 2026. She provided notice on May 18, 2026, allowing a short transition period before Chief Financial Officer Misbah Tahir assumes principal accounting officer responsibilities.

After June 1, 2026, Maze Therapeutics’ Chief Financial Officer, Misbah Tahir, will be designated as the company’s principal accounting officer. This change places both overall financial leadership and formal accounting responsibilities under the CFO function at the company.

This Maze Therapeutics 8-K relates to Item 5.02, which covers departures and appointments of directors or certain officers and compensatory arrangements. The filing specifically addresses the resignation of the Senior Vice President of Finance and the reassignment of principal accounting officer duties.

Date: May 22, 2026

/s/ Courtney Phillips

Courtney Phillips

General Counsel and Corporate Secretary

3 documents